3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Pancreatic Neoplasms
1
Nasopharyngeal Carcinoma
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
venetoclax
14
ibrutinib
11
Rituximab
9
obinutuzumab
8
Specimen Handling
7
Cyclophosphamide
7
acalabrutinib
6
Biopsy
6
zanubrutinib
5
pirtobrutinib
5
fludarabine phosphate
4
Lenalidomide
4
ARQ531
4
idelalisib
3
Whole-Body Irradiation
3
Magnetic Resonance Spectroscopy
3
Cyclosporine
3
fludarabine
2
Vincristine
2
Sirolimus
2
Prednisone
2
Mycophenolic Acid
2
Doxorubicin
2
CT-P10
2
Bendamustine Hydrochloride
2
treosulfan
1
tocilizumab
1
pembrolizumab
1
mirdametinib
1
Tacrolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Lymphocytic, Chronic, B-Cell
×
Maintenance
×
30 days
×
Clear all
NCT04542824
2026-06-02
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2
Active not recruiting
78 enrolled